Navigation Links
Consortium to design human trials of mosaic HIV vaccine
Date:10/18/2010

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

The team and its efforts are being led by Duke University Medical Center under consortium leader Dr. Barton Haynes, director of the Duke Human Vaccine Institute and the Center for HIV/AIDS Vaccine Immunology (CHAVI). The newly formed research coalition has begun designing an early phase safety trial to assess mosaic vaccines in humans. The trial will test the mosaic concept and could lead to the next generation of HIV vaccine candidates.

Traditional HIV vaccines are designed to stimulate the body's immune system to recognize naturally occurring stretches of specific amino acids in the virus' proteins. In contrast, mosaic vaccines are composed of many sets of synthetic, computer-generated sequences of proteins that can prompt the immune system to respond to a wide variety of circulating HIV strains.

Such vaccines have already been studied in animals and have shown some success in enhancing the breadth of immune responses. Results of those studies appeared earlier this year in Nature Medicine.

Haynes said the group will use the NYVAC vaccinia vector (derived from the vaccine to protect against smallpox) and DNA that contain a new set of artificial, computer-designed HIV genes in a Phase-I clinical trial to be supported by the Bill & Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Haynes says the consortium hopes to launch human trials by late 2012.

Korber, a senior researcher in Los Alamos National Laboratory's Theoretical Division, led the team that developed the mosaic genes.

"HIV's diversity is vast, and the mosaic gene design represents a novel vaccine design to directly tackle HIV diversity in human clinical trials," said Korber. "Based on computational models, mosaic vaccines were predicted to perform better than natural HIV genes; experimental studies in animals, which directly compared mosaic to natural vaccines, supported that prediction. We are excited to test this concept in humans."

The consortium includes many of the world's leading researchers and organizations committed to finding an effective vaccine to protect against HIV infection, including The Foundation for the National Institutes of Health, the Fred Hutchinson Cancer Research Center and its NIH-funded HIV Vaccine Trials Network, the IPPOX Foundation in Switzerland, Beth Israel Deaconess Medical Center, Los Alamos National Laboratory, the NIH/NIAID Vaccine Research Center, Duke University and its Center for HIV/AIDS Vaccine Immunology, the Bill & Melinda Gates Foundation and the Division of AIDS of the National Institute of Allergy and Infectious Diseases.

"Each member of this consortium is also a member of the Global HIV Vaccine Enterprise, and this collaboration is truly a global effort to make progress on HIV vaccine development," said Haynes.


'/>"/>

Contact: James E. Rickman
jamesr@lanl.gov
505-665-9203
DOE/Los Alamos National Laboratory
Source:Eurekalert

Related biology news :

1. Aeras-led research consortium receives FDA support
2. Structural Genomics Consortium releases 1,000th protein structure
3. Aware to Introduce Several New Software Products at the Biometrics Consortium Conference
4. AOptix Technologies to Show Combined Biometric Face and Iris Capture System at Biometrics Consortium Conference
5. DOE awards UC San Diego consortium $9 million for algal biofuels research
6. WHOI joins consortium to study, minimize effects of Gulf Oil spill
7. Biomedical research infrastructure goes global: EU consortium Infrafrontier has new partners
8. Duke and the International Serious Adverse Event Consortium to partner on research
9. Duke and the Internationalserious Adverse Event Consortium to partner on research
10. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
11. $15 million stimulus award creates national consortium for revealing scientific resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScanĀ® technology provides the fastest and most accurate ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
Breaking Biology Technology: